Porton Pharma Solutions Ltd.

Shenzhen Stock Exchange 300363.SZ

Porton Pharma Solutions Ltd. Receivables for the year ending December 31, 2023: USD 103.60 M

Porton Pharma Solutions Ltd. Receivables is USD 103.60 M for the year ending December 31, 2023, a -52.53% change year over year. Receivables are the amounts owed to the company by customers for goods sold or services rendered.

Porton Pharma Solutions Ltd. Receivables for the year ending December 31, 2022 was USD 218.25 M, a 27.49% change year over year.
Porton Pharma Solutions Ltd. Receivables for the year ending December 31, 2021 was USD 171.19 M, a 175.68% change year over year.
Porton Pharma Solutions Ltd. Receivables for the year ending December 31, 2020 was USD 62.10 M, a 19.26% change year over year.
Porton Pharma Solutions Ltd. Receivables for the year ending December 31, 2019 was USD 52.07 M, a 35.16% change year over year.

Key data

Date	Receivables	Inventory	Goodwill	Total Assets

Shenzhen Stock Exchange: 300363.SZ

Porton Pharma Solutions Ltd.

CEO	Mr. Nianfeng Ju
IPO Date	Jan. 29, 2014
Location	China
Headquarters	Fangzheng Avenue
Employees	4,915
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Porton Pharma Solutions Ltd. manufactures and supplies small molecule active pharmaceutical ingredients and drug intermediates, dosage forms, and biologics to the pharmaceutical companies. The company was formerly known as Porton Fine Chemicals Ltd. and changed its name to Porton Pharma Solutions Ltd. in January 2018. Porton Pharma Solutions Ltd. was founded in 2005 and is headquartered in Chongqing, China.

Key trends

Past 5 years